| Literature DB >> 25445466 |
Anjali Varma Desai1, Hassan El-Bakkar1, Maher Abdul-Hay2.
Abstract
Half of a century ago, physicians managing chronic lymphocytic leukemia (CLL) recognized some of its presenting features such as lymphocytosis, lymphadenopathy, and splenomegaly. Subsequently, an enhanced understanding of the disease mechanisms involved in CLL led to new, more targeted treatments. There is now a plethora of treatments available for CLL. In this review article we discuss in detail several of the novel agents that are being studied or approved for the treatment of CLL including: phosphatidylinositol 3-kinase inhibitors (idelalisib and IPI-145), Bruton tyrosine kinase inhibitors (ibrutinib), B cell lymphoma 2 inhibitors (ABT-263 and ABT-199), new anti-CD20 monoclonal antibodies (obinutuzumab), cyclin-dependent kinase inhibitors (flavopiridol and dinaciclib), immunomodulators (lenalidomide) and chimeric antigen receptor T-cell therapy.Entities:
Keywords: B cell lymphoma 2 inhibitors; Bruton tyrosine kinase inhibitors; CDK inhibitors; Immunomodulators; PI3K inhibitors
Mesh：
Substances：
Year: 2014 PMID： 25445466 DOI： 10.1016/j.clml.2014.09.007
Source DB: PubMed Journal: Clin Lymphoma Myeloma Leuk ISSN： 2152-2669